Psoriasis is a chronic inflammatory skin disease affecting 1% to 3% of the world’s population1. A considerable proportion of patients with psoriasis will develop a form of inflammatory arthritis known as psoriatic arthritis (PsA). More rarely, PsA develops before the psoriatic lesions. The prevalence of PsA in patients with psoriasis varies from 7.6% to 36% according to the different populations studied2.
The inadequate response to treatment and the toxicity of traditional treatments opened the doors to the development of new therapeutic alternatives such as tumor necrosis factor-α (TNF-α) antagonists, which are utilized in patients with PsA and psoriasis for reducing the proinflammatory cell infiltration (macrophages, monocytes, keratinocytes, Langerhan’s cells, dermal dendritic cells, mast cells, and activated T cells) at the skin and synovial level3,4.
Some authors have demonstrated the utility of ultrasound (US) in PsA5,6, but to our knowledge no studies have aimed at assessing the potential of this technique in anti-TNF-α therapy …